Canadian Journal of Gastroenterology and Hepatology / 2019 / Article / Tab 5

Research Article

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 5

Possible reason of nonresponse to rescue therapy.

PatientGTFPrimary therapyOut comeSecondary therapyETRMonths between therapiesRASComments

134OBV/PTV/r
+DSV+RBV
12 weeks
RELLDV/SOF
+RBV
12 weeks
YES6after therapy:
Not detected
wrong regimens - initially diagnosed as G1b;

161B4LDV/SOF
+RBV
12 weeks
RELLDV/SOF
+RBV
24 weeks
YES9Not doneretreatment with the same regimen - possible RAS to NS5A

221B4LDV/SOF
+RBV
12 weeks
NRSOF+DCV
+RBV
24 weeks
NO14Not doneunknown non-response reason - possible RAS to NS5A

231B4ASV+DCV
24 weeks
NROBV/PTV/r
+DSV+RBV
12 weeks
NO4Before therapy:
NS3: S122R, D168E;
NS5A: L31V, Y93H
RAS to NS3 and NS5A

GT: genotype; F: fibrosis; ETR: end of treatment; RAS: resistance associated substitution; NS3: nonstructural protein 3; NS5A: nonstructural protein 5A; NR: nonresponder; REL: relapse; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; SMV: simeprevir.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.